Lixivaptan

Lixivaptan

Clinical data
ATC code	none
Identifiers
IUPAC name N-[3-chloro-4-(6,11-dihydropyrrolo[2,1-c] [1,4]benzodiazepine-5-carbonyl)phenyl]-5-fluoro-2-methylbenzamide
CAS Number	168079-32-1 N
PubChem CID	172997
IUPHAR/BPS	2238
ChemSpider	151067 N
UNII	8F5X4B082E
ChEMBL	ChEMBL49429 N
CompTox Dashboard (EPA)	DTXSID00168472
ECHA InfoCard	100.126.016
Chemical and physical data
Formula	C27H21ClFN3O2
Molar mass	473.93 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1c2cccn2Cc3ccccc3N1C(=O)c4ccc(cc4Cl)NC(=O)c5cc(F)ccc5C
InChI InChI=1S/C27H21ClFN3O2/c1-17-8-9-19(29)13-23(17)26(33)30-20-10-11-22(24(28)14-20)27(34)32-16-21-6-4-12-31(21)15-18-5-2-3-7-25(18)32/h2-14H,15-16H2,1H3,(H,30,33) N Key:PPHTXRNHTVLQED-UHFFFAOYSA-N N
NY (what is this?)  (verify)

Lixivaptan (VPA-985) is an orally-active, non-peptide, selective vasopressin 2 receptor antagonist being developed as an investigational drug by Palladio Biosciences, Inc. (Palladio), a subsidiary of Centessa Pharmaceuticals plc. As of December 2021^[update], lixivaptan is in Phase III clinical development for the treatment of Autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to lixivaptan for the treatment of ADPKD.